Summit Therapeutics Inc.

NasdaqGM SMMT

Summit Therapeutics Inc. Price to Sales Ratio (P/S) on January 14, 2025

Summit Therapeutics Inc. Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Summit Therapeutics Inc. 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
Summit Therapeutics Inc. 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
Summit Therapeutics Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: SMMT

Summit Therapeutics Inc.

CEO	Mr. Robert W. Duggan
IPO Date	March 5, 2015
Location	United States
Headquarters	One Broadway
Employees	105
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Key trends

Past 5 years